IGF1 and Alzheimer disease: As circulating IGF-1 is a prominent biomarker for cognitive decline across multiple domains in aging, MCI, and AD (27, 28), and based on our previous findings that unveiled several commonalities between CP and MCI (2), we postulated that circulating IGF-1 could be a biological determinant and hence be associated with cognitive functions in CP.